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A B S T R A C T
Background
Defaulting from treatment remains a challenge for most tuberculosis control programmes. It
may increase the risk of drug resistance, relapse, death, and prolonged infectiousness. The aim
of this study was to determine factors predicting treatment adherence among smear-positive
pulmonary tuberculosis patients.
Methods and Findings
A cohort of smear-positive tuberculosis patients diagnosed and registered in Hossana
Hospital in southern Ethiopia from 1 September 2002 to 30 April 2004 were prospectively
included. Using a structured questionnaire, potential predictor factors for defaulting from
treatment were recorded at the beginning of treatment, and patients were followed up until
the end of treatment. Default incidence rate was calculated and compared among
preregistered risk factors. Of the 404 patients registered for treatment, 81 (20%) defaulted
from treatment. A total of 91% (74 of 81) of treatment interruptions occurred during the
continuation phase of treatment. On a Cox regression model, distance from home to treatment
centre (hazard ratio [HR]¼ 2.97; p , 0.001), age . 25 y (HR¼ 1.71; p¼ 0.02), and necessity to
use public transport to get to a treatment centre (HR ¼ 1.59; p ¼ 0.06) were found to be
independently associated with defaulting from treatment.
Conclusions
Defaulting due to treatment noncompletion in this study setting is high, and the main
determinants appear to be factors related to physical access to a treatment centre. The
continuation phase of treatment is the most crucial time for treatment interruption, and future
interventions should take this factor into consideration.
The Editors’ Summary of this article follows the references.
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Introduction
As much as untreated tuberculosis (TB) threatens the well
being of an individual and society, defaulting from treatment
may increase the risk of drug resistance, relapse, and death,
and may prolong infectiousness [1–3]. In resource-con-
strained settings where the health care services are not well
developed, delayed presentation for treatment and defaulting
from treatment are the two major challenges that TB
programmes face [4]. The idea of direct observation of
treatment (DOT) evolved from the need to improve treat-
ment adherence. However, the role of DOT in maintaining
treatment adherence appears to be surrounded by contro-
versies. Reports from many countries favour DOT as a key
component in the Directly Observed Treatment—Short
Course (DOTS) strategy, a global strategy recommended by
the World Health Organization for the prevention and
control of TB [5–7]. Conversely, some randomised controlled
studies have failed to establish the superiority of DOT over
the conventional nonobserved treatment in improving treat-
ment adherence [8,9]. As such, ensuring successful treatment
completion might require addressing multiple factors beyond
simple supervision of drug intake [10–14].
TB continues to be a major public health problem in
Ethiopia, which ranks seventh by estimated number of cases
among the 22 TB high-burden countries [15]. Before the
introduction of DOTS in Ethiopia, 82% of TB patients were
reported to have failed to complete treatment [16], while
defaulting from DOTS in a southeastern part of the country
was reported to be as low as 11.3% [17]. In the southern
region of Ethiopia (Southern Nations Nationalities and
Peoples’ Regional State), DOTS was introduced in 1996. An
earlier study on the impact of DOTS in the region reported a
signiﬁcantly declining trend in treatment noncompletion
from 38% to 18% over six years during 1994–2000 [18].
However, one in ﬁve patients still continued to default from
treatment, and its predictors are not well understood. Apart
from physical access, such factors as socioeconomic status,
educational level, and patient satisfaction with the care
provided may inﬂuence treatment adherence. In an effort to
reach the global target of 85% treatment success, it was
compelling to identify, describe, and deal with factors
determining treatment adherence. The current study, there-
fore, was aimed at determining factors that predict treatment
adherence among the most infectious form of TB, smear-
positive pulmonary TB (PTBþ) patients.
Methods
Setting
This study was conducted among smear-positive TB
patients diagnosed at Hossana Zonal Hospital in the Hadiya
zone of the southern region of Ethiopia. The hospital serves
as a referral centre for the population of Hadiya and three
adjacent zones (approximately 2.5–3 million people). The
health facilities within these zones register and treat all
diagnosed TB patients under the DOTS. All diagnosed TB
cases are registered at the unit registers, compiled at the
district registers, and reported to the regional TB pro-
gramme. Once diagnosed with TB, patients are provided with
anti-TB medication and care free of charge. In line with the
national TB and leprosy control programme guidelines [19],
all new cases of TB are treated with short-course chemo-
therapy comprising two months on rifampicin, isoniazid, and
pyrazinamide (RHZ) plus ethambutol (E) or streptomycin (S)
during the initial phase of treatment. During this intensive
phase, health care providers directly observe patients while
they are taking daily treatment. This phase is followed by a
continuation phase of six months on EH, during which time
drugs for self-administered treatment are to be collected
every month. Retreatment cases (return after default, relapse,
or treatment failure cases) are treated with SERHZ for two
months, followed by one month on ERHZ, and ﬁve months on
ERH. Fixed dose combinations are used throughout the
treatment period. Most TB cases are treated on ambulatory
basis, with the exception of a few patients requiring
admission for medical reasons. Those living in rural areas
far away from the diagnostic centre are referred to the
nearest health facility for treatment initiation and follow-up.
Design and Data Collection
A cohort of PTBþ patients diagnosed and registered for
treatment in Hossana Hospital from 1 September 2002 to 30
April 2004 were prospectively included. All smear-positive TB
cases registered over the study period were included. Using
structured interview questionnaires, sociodemographic, be-
havioural, and environmental factors that could potentially
predict defaulting from treatment were recorded at the
commencement of treatment. Data were also gathered on
patient–provider interactions and satisfaction with the initial
reception during the diagnostic process. Family income was
calculated based on reported monthly salary for paid work-
ers, monthly income from petty trade or daily labour, and/or
prices and quantity of annual agricultural production divided
by twelve months. Distance was calculated both in terms of
number of hours an average person has to walk to reach the
health facility from residence, and in terms of actual physical
distance (in km) from home to the health facility.
The interviews were conducted by two trained nurses in the
hospital. Informed oral consent was obtained from each
individual upon enrolment to the study. All patients were
followed throughout the treatment period, and any special
event on the due course of treatment as well as treatment
outcomes were documented. Health care workers in the TB
clinics of the respective health facilities provided treatment,
followed patients, and recorded outcomes. The principal
investigator and a data clerk visited each health facility and
collected the data on treatment outcomes. Two trained data
collectors (high school graduates) traced and interviewed the
defaulters and advised them to resume treatment.
A default case was deﬁned as PTBþ patient who has been
on treatment for at least four weeks and whose treatment was
interrupted for more than eight consecutive weeks [19].
Treatment success was deﬁned as cure (smear-negative at
treatment completion and on at least one previous occasion),
plus treatment completion without conﬁrmation by smear-
microscopy. Default rate in each stratum of the predictor
factors was calculated against total person-time of observa-
tion. All defaulters were traced and interviewed regarding the
main reason for defaulting from treatment. After the inter-
view each defaulter was encouraged to get back to treatment
at the nearest health facility of choice.
We calculated the sample size for the desired effect (HR) of
2.0 with 5% level of signiﬁcance and 90% power assuming
PLoS Medicine | www.plosmedicine.org February 2007 | Volume 4 | Issue 2 | e370002
TB Treatment Adherence in Ethiopia
that one-fourth of exposed and one-tenth of unexposed
patients would default from treatment, based on an average
default rate of 20% from a previous study [18].
Data were entered and analysed using SPSS for windows
version 12.0.1 (SPSS, http://www.spss.com). Continuous varia-
bles were analysed using independent sample t-test. Chi2 tests
and HRs with 95% conﬁdence intervals (95% CIs) were used
to evaluate categorical data. The independent effect of each
potential predictor variable (adjusted HR) was assessed using
a Cox regression model with a backward ﬁtting algorithm.
Multiple responses to open-ended questions were recoded at
the end of data entry, and each response was analysed
independently.
The study was approved by the Regional Committee for
Medical Research Ethics in Western Norway (REK Vest) and
the Ethics Committee of Southern Nations Nationalities and
Peoples’ Regional State Health Bureau in Ethiopia.
Results
Figure 1 shows the ﬂow of study participants. A total of 404
new PTBþ patients were registered for treatment between 1
September 2002 and 30 April 2004. Of these, 82% (n ¼ 331)
were from Hadiya zone and 43% (n ¼ 174) were female
patients. A total of 21% (n¼83) of the patients had treatment
follow-up at Hossana Hospital, whereas 43% (n ¼ 169) and
36% (n ¼ 139) were treated at the health centres and health
stations, respectively. A total of 199 patients (49%) volun-
teered to have HIV testing, of which 12% (25 out of 199) were
positive for HIV. A total of 81 patients (20%) defaulted from
treatment, while 310 (77%) successfully completed treatment;
nine (2.2%) died, one had treatment failure, and three had
moved outside the region and could not be traced. Table 1
presents the baseline characteristics of the study participants.
During the ﬁrst two months following the intensive phase,
two-thirds of the defaulters interrupted treatment. Overall,
91% of the incidences of defaulting from treatment occurred
during the continuation phase of treatment (Table 2).
In univariate analysis, factors signiﬁcantly associated with
treatment noncompletion included participant over the age
of 25 y, rural residence, educational level, occupation,
distance from residence to the nearest treatment centre,
need for public transport to get to a treatment centre, and
the patient’s condition on treatment initiation, as shown in
Table 3. No signiﬁcant association was noted between default
from treatment and gender, average family income, HIV
status, treatment centre, prior knowledge about TB, and
knowledge about treatment duration.
In multivariate analysis, three variables—age, distance from
home to treatment centre, and need to use public transport
to get to a treatment centre—appeared in the last step of the
Cox regression model with backward elimination. Both
forward and backward ﬁttings produced the same model.
After simultaneously controlling for the potential predictor
variables, distance from home to treatment centre (HR¼2.97;
p , 0.001), age over 25 y (HR¼1.71; p¼0.02), and necessity to
use public transport to get to a treatment centre (HR¼1.59; p
¼ 0.06) remained independent risk factors for treatment
noncompletion (Table 3). Figure 2 shows time on treatment
by walking distance from treatment centre, adjusted by Cox
regression analysis.
It was possible to trace and advise 74 of the 81 defaulters to
resume medication. A single open-ended question was posed
to each defaulter case before advising them to resume
treatment, ‘‘Can you tell me why you discontinued taking
TB medication before the required period?’’ As shown in
Table 4, the major reasons given by 45% of the patients for
interrupting treatment were those related to physical access
(TB clinic too far from home, could not afford transportation
cost, and too tired to walk to the treatment centre).
Erroneous sense of cure, loss of hope in the medication,
and inadequate knowledge about treatment duration were
also among the reasons mentioned by the patients.
Discussion
This study tried to measure the extent and predictors of
treatment noncompletion in a predominantly rural society. A
total of one-ﬁfth of the registered PTBþ cases failed to
complete treatment. This ﬁnding conﬁrms an earlier study
report that documented a declining trend in default rate
from 38% to 18% over a six-year period from 1994 to 2000
[18]. The default rate in our study is lower compared to
previous studies in some African countries [16, 20–22].
However, it is higher than the 11.6% default rate from DOTS
reported in Arsi zone of Ethiopia [17]. Treatment non-
completion is required to fall below 10% in order to achieve
treatment success of 85%, one of the health-related indica-
tors of the Millennium Development Goals [15].
Most of the factors associated with treatment noncomple-
tion, apart from the patient’s age and level of education, are
those related to physical access to health-care services:
distance from home to treatment centre, rural residence,
and a need to use public transport for ambulatory care. A
single open-ended question to the defaulters also elucidated
responses that are consistent with this ﬁnding. In other
settings, risk factors such as knowledge about treatment
duration, change of treatment unit, running out of drugs,
poor patient–health provider communication, and medica-
tion side effects were reported to have been associated with
treatment noncompletion [17, 21–25].
The prospective design of this study has allowed recording
of potential risk factors for treatment noncompletion at the
beginning of the study. As a result, the risk of recall bias,
which is an inherent problem of retrospective study designs,
is taken into account. This design would also help to predict
the probability of defaulting from treatment right at the start
Figure 1. Study Profile
doi:10.1371/journal.pmed.0040037.g001
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of treatment based on the patient’s sociodemographic and
environmental context. However, this approach has its own
limitations. For example, events during the course of treat-
ment, such as drug side effects and care provider–patient
interactions, which could considerably inﬂuence a patient’s
decision to continue treatment, were not measured. Such
factors cannot be recorded at the beginning of the study, and
a combined approach may have yielded better results.
Furthermore, fewer than half of the patients volunteered
for HIV screening, and as a result, we are not able to
determine how much, if at all, HIV status inﬂuences
treatment adherence in our study setting.
While it is recognised that only half of the population in
this setting lives within reach of a health facility in a two-hour
walk [26], 72% of the patients in our study cohort came from
within this circle. Fewer patients came from areas not within
reach of a health facility in a two-hour walk, and nearly half of
these patients failed to complete treatment. As such, physical
access seems to be the most signiﬁcant determinant of
treatment noncompletion in this predominantly rural setting,
and its role in health-care seeking warrants further inves-
tigation. Age also appears to be another signiﬁcant predictor
for defaulting in this setting. One possible explanation is that
older people assume more family responsibility and, as a
result, this group of individuals may tend to stop medication
when they feel better or when they come across more
Table 1. Baseline Characteristics of Smear-Positive TB Patients Registered for Treatment in Hossana Hospital from 1 September 2002 to
30 April 2004
Characteristic Group Number Registered Number (%) Defaulted p-Valuea
Gender Male 230 44 (19) 0.59
Female 174 37 (21)
Age group in years 14 21 4 (19) 0.17
15–24 174 26 (15)
25–34 114 31 (27)
35–44 55 11 (20)
45 40 9 (23)
Marital status Married 201 46 (23) 0.16
Not married 203 35 (17)
Education Literate 228 36 (16) 0.01
Nonliterate 174 45 (26)
Occupation Student 102 13 (13) 0.03
Farmer 171 44 (26)
Other 131 24 (18)
Family size 1–4 84 15 (18) 0.55
5 317 66 (21)
Monthly family income (Birr)b 0–99 199 39 (20) 0.93
100–199 123 27 (22)
200 82 15 (18)
Duration of symptomsc 30 d 30 4 (13) 0.07
31–90 d 156 26 (17)
.90 d 218 51 (23)
Residence Urban 64 6 (9) 0.02
Rural 340 75 (22)
Zone of residence Hadiya zone 331 56 (17) 0.001
Outside Hadiya zone 73 25 (34)
Distance to diagnostic centre 10 km 111 12 (11) 0.004
.10 km 293 69 (24)
Distance to treatment centre 10 km 352 54 (15) ,0.001
.10 km 52 27 (52)
av2-test for trend
b1 USD¼ 8.60 Ethiopian Birr as of April 2004.
cSymptom duration at treatment initiation.
doi:10.1371/journal.pmed.0040037.t001
Table 2. Time of Default from Treatment among the 81 Defaulters
Time of Default from Treatment Frequency Number (%) Cumulative Frequency Number (%)
2nd month 7 (8.6) 7 (8.6)
3rd month 29 (35.8) 36 (44.4)
4th month 25 (30.9) 61 (75.3)
5th month 9 (11.1) 70 (86.4)
6th month 8 (9.9) 78 (96.3)
7th month 3 (3.7) 81 (100)
doi:10.1371/journal.pmed.0040037.t002
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pressing social obligations. It is also possible that older people
gain less attention in the provision of health care, and this
warrants further investigation.
Although 15% of defaulters in our study mentioned that
they stopped taking medication because they thought they
had completed the treatment, there was no statistically
signiﬁcant difference between the defaulters and nondefault-
ers with regard to knowledge about treatment duration.
There was also no difference between these groups regarding
intention to discontinue treatment if and when their
symptoms disappeared. However, 26% of defaulters men-
tioned ‘‘feeling better’’ as the main reason for discontinuing
treatment. This indicates that distance, the strongest pre-
dictor of treatment interruption in this area, may act
synergistically with other factors such as feeling better, loss
of hope, unaffordable transportation costs, and drug side
effects to inﬂuence adherence to treatment. Future research
in this area should address the complex interplay between
such factors and explore possible interventions to improve
treatment adherence. Decentralisation of treatment follow-
up to community health posts and improved patient–
provider communication on treatment duration are among
options to be explored further. Peer-encouragement mech-
anisms such as the formation of ‘‘TB clubs’’ have also been
shown to be an effective community-based approach in
enhancing treatment completion [27,28]. In an effort to
reduce the access gap to health care, the Ethiopian govern-
ment has started a new community-based initiative called the
‘‘Health Service Extension Programme.’’ Under this pro-
gramme, thousands of health extension agents have been
identiﬁed and trained, which might help to enhance case-
holding under the DOTS programme through decentral-
isation of services in the country [29].
In this study, more than 90% of the defaulters discontinued
treatment during the continuation phase of treatment,
particularly during the ﬁrst two months following the two-
month intensive phase of treatment. One of the explanations
for this ﬁnding might be that during this phase most of the
symptoms disappear and patients may erroneously believe
they are cured. This may encourage them to become
reluctant to bear the extra burden of the cost of travel, time,
and drug side effects. On the contrary, the condition may
remain the same or even be worsened by such conditions as
HIV/AIDS or resistance of the bacilli to anti-TB medication,
and patients may lose hope for improvement after having
made every effort during the ﬁrst two months. A better
understanding of treatment default timing in most patients
may help programme managers to better plan ahead for how
to reduce this problem. Furthermore, the importance of good
rapport between patients and care providers in proper
treatment adherence cannot be overemphasised.
Although the reported death rate in this study cohort is
only 2.2%, there is a possibility of more deaths among
patients who defaulted from treatment. Unfortunately, we do
not have sufﬁcient information on the ﬁnal status of these
defaulters after the initial contact and advice to resume
treatment. Likewise, only one of 404 patients was reported to
have treatment failure, which is unlikely with the current
eight-month regimen used in this study setting [30]. Nearly
half of smear-positive TB patients do not have a follow-up
sputum examination in this set-up [18], and as a result this
reported failure rate is likely to be an underestimate.
In conclusion, defaulting from treatment in this study
setting was high, and the main determinants appear to be
factors related to physical access to a treatment centre. The
continuation phase of treatment is the most crucial time for
defaulting from treatment, and future interventions should
take this into consideration.
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Figure 2. Survival Curve of Time on Treatment by Walking Distance from
Treatment Centre, Adjusted by Cox Regression Analysis
doi:10.1371/journal.pmed.0040037.g002
Table 4. Reasons for Defaulting from Treatment (n¼ 74)
Main Reason Number Percentage
TB clinic too far from home 21 28.4
Felt better and needed no more drugs 19 25.7
Thought to have completed treatment 11 14.9
Too tired (weak) to walk to TB clinic 8 10.8
Could not tolerate medication 5 6.7
Condition worsened/did not improve 5 6.7
Could not afford transportation cost 4 5.4
Dissatisfied by the care provided 1 1.4
doi:10.1371/journal.pmed.0040037.t004
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Editors’ Summary
Background. Tuberculosis (TB) is one of the leading causes of death
from infectious disease worldwide, and it kills around 1.7 million people
each year. TB can be successfully treated but the treatment course is
long (at least six months). In 1995 the World Health Organization set up
‘‘DOTS’’, an international strategy for TB control. One of the links below
explains what DOTS is in more detail. One of the main elements of DOTS
involves the use of standard courses of drug treatment, with the
recommendation that trained observers watch people take their
treatment. These steps should prevent people from failing to complete
their course of treatment, and the World Health Organization has set a
target level of 85% for treatment success. However, people do often
have problems sticking to treatment and the reasons for this are not
clearly understood. Factors such as access to care and a person’s social
and financial situation might affect whether an individual sticks to their
prescribed treatment.
Why Was This Study Done? This study was carried out in Ethiopia,
which has been recognized as being in the top 22 countries with the
highest burden of tuberculosis. In the region of southern Ethiopia
studied, the proportion of patients not completing their treatment has
declined from 38% to 18% between 1994 and 2000. However, the World
Health Organization’s targets have not been met, with 20% of patients
currently failing to complete treatment. These researchers wanted,
therefore, to identify the factors that play a part in determining whether
a patient completes their course of treatment. They hope that once such
factors are identified, they could ultimately be overcome with
appropriate interventions and the level of treatment success improved.
What Did the Researchers Do and Find? The researchers carried out a
cohort study, in which all patients diagnosed with clinical tuberculosis
during a particular period of time at a major regional hospital in southern
Ethiopia were included. Patients were followed up throughout their
treatment course and then counted as either having defaulted from
treatment (if they had been on treatment for at least 4 weeks and then
interrupted for at least 8 weeks), or having completed. The researchers
carried out interviews with each participant at the start of the study, to
collect information on factors which might affect how each participant
might stick to their treatment plan. These factors included basic
information such as whether the patient was male or female, their age,
marital status, educational level and occupation, as well as others
including family income, whether their home was rural or urban, and the
distance to the treatment centre. Finally, patients who stopped their
treatment were asked an open-ended question: ‘‘Why did you stop
taking TB medication?’’
404 patients were included in the study and 20% defaulted, most of
these within the first few months of treatment. The researchers found
that a number of factors seemed to be linked to an increased chance
that the person would default from treatment. These included age
(patients over 25 were less likely to complete); living in a rural setting;
having a lower level of education; greater distances from home to the
treatment centre; the need for transport to get to treatment; and
whether the patient was admitted to hospital in a serious condition.
When defaulters were questioned about the reasons they did not
complete treatment, the main reasons were related to physical access to
the treatment clinic—for example that it was too far, they could not
afford to get there, or were not able to walk to get treatment.
What Do These Findings Mean? The proportion of patients failing to
complete their tuberculosis treatment here supports the view that the
default rate in Ethiopia has been falling over the past two decades; but
that it is still higher than that recommended by the World Health
Organization. The researchers also found that physical access to
treatment poses a significant barrier to completing treatment. In this
study 72% of patients were within two hours’ walk of the health facility, a
much greater proportion than is the case for the general population in
that region. These findings suggest that government initiatives will be
needed in order to address the problem of access to treatment and
therefore improve adherence. New initiatives are underway in Ethiopia to
train health service workers who can provide community-based care.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
00400037.
 World Health Organization (WHO) fact sheet on tuberculosis. More
detailed information from WHO is available on DOTS, including the
five key elements of DOTS
 The US Centers for Disease Control and Prevention has a minisite
dedicated to tuberculosis, including a questions-and-answers page
 The Stop TB Partnership was established in 2000 to realize the goal of
eliminating TB as a public health problem and, ultimately, to obtain a
world free of TB. It comprises a network of international organizations,
countries, donors from the public and private sectors, governmental
and nongovernmental organizations, and individuals that have
expressed an interest in working together to achieve this goal
 Me´decins Sans Frontie`res, an international medical humanitarian
organization, has information on its website about its activities in
Ethiopia
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